SecuritySGYP / Synergy Pharmaceuticals, Inc.
InstitutionCVI Investments, Inc.
Shares12,337,116
Ownership 4.80%
Related 871639AA8 / Synergy Pharmaceuticals, Inc., 7.5% Convertible Bond due 2019
SGYPW / Synergy Pharmaceuticals, Inc., Warrants

CVI Investments, Inc. discloses 4.80% ownership in SGYP / Synergy Pharmaceuticals, Inc.

February 09, 2018 - CVI Investments, Inc. has filed an SC 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 12,337,116 shares of Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP). This represents 4.8 percent ownership of the company. In their previous filing dated November 22, 2017, CVI Investments, Inc. had reported owning 19,379,845 shares, indicating a decrease of -36.34 percent.

Synergy Pharmaceuticals, Inc. has declared a standard industrial code (sic) of 2834 which is the "Pharmaceutical Preparations" industry.

13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date
Effective
Date
Form Prev
Shares
Reported
Shares
Change in Shares
(Percent)
Ownership
(Percent)
Change in Ownership
(Percent)
2018-02-09 2018-02-09 SC 13G/A 19,379,845 12,337,116 -36.34 4.80 -39.24
2017-11-22 2017-11-22 SC 13G 19,379,845 7.90
SGYP: Synergy Pharmaceuticals Stock Analysis and Research Report

2017-09-29 - Asif

Synergy Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies. The company has pioneered discovery, research and development efforts around analogs of uroguanylin, a naturally occurring and endogenous human GI peptide, for the treatment of GI diseases and disorders. The company discovered, are developing and control 100% worldwide rights to its proprietary uroguanylin based GI platform, which includes one commercial product, TRULANCE (plecanatide), and a second product candidate, dolcanatide. TRULANCE (plecanatide) Its first and only commercial product, TRULANCE™, is approved and marketed in the United States (U.S.), under the trademark name TRULANCE™, as a once-daily treatment for adults with chronic idiopathic constipation, or CIC. In clinical trials, TRULANCE helped improve stool consistency and provide more regular bowel movements. TRULANCE is the only prescription medication for CIC that c...



CUSIP: 871639308